Market Overview

Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome


Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine. Discovery Labs anticipates that SURFAXIN will be commercially available in the United States in late 2012.

Posted-In: News FDA


Related Articles (DSCO)

View Comments and Join the Discussion!

Phase 3 Long-Term Safety Trial Results of Lubiprostone in Patients with Irritable Bowel Syndrome with Constipation was Recently Published in Alimentary Pharmacology and Therapeutics

These Death Cross ETFs Could be in Big Trouble (EGPT, DFE, FAA)